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TO THE EDITOR: The article by Cannesson et al. (1) convincingly
explains several analogous changes on dynamic preload vari-
ables, which we have only recently been able to monitor
noninvasively in daily patient care. Although phenylephrine
has been in clinical use for decades, measurements of advanced
hemodynamic variables in a beat-to-beat fashion are regretta-
bly much more laborious than simple blood pressure assess-
ment, resulting in considerable bias among clinicians of its
overall clinical effects.
Our observations using the Nexfin (Edwards Lifesciences
BMEYE, Amersterdam, The Netherlands) monitor during rou-
tine clinical practice for continuous noninvasive monitoring of
advanced hemodynamic variables manifestly confirms the dis-
tinct effects of phenylephrine on venous return and global
hemodynamics as reported by Cannesson et al. However, an
important issue to properly interpret the effects of phenyleph-
rine on stroke volume (SV), stroke volume variation (SVV), or
respiratory variations in pulse pressure (PPV) is considering its
effect on heart rate (HR). In the Cannesson et al. report, there
was no significant bradycardia—most probably because of
atropine premedication—but this common effect of phenyl-
ephrine may conceivably result in an increase in SV resulting
from an increased diastolic filling. In that case, an increase in
SV is (at least) not an exclusive beneficial result of improved
venous return. Equally, a decrease in SVV or PPV may be a
result of decreased cardiac output (CO) with subsequent in-
creased venous pooling.
Interestingly, atropine is often administered prophylactically
in anticipation of vagal stimulating ophthalmic interventions,
largely preventing the reflex bradycardia of phenylephrine.
As we now routinely monitor advanced hemodynamics in
these patients using the noninvasive Nexfin device, we took the
opportunity to evaluate the evolution of SV, SVV, and PPV in
relation to HR and CO in patients who were parasympathically
blocked vs. non-parasympathically blocked with atropine and
received 100 g phenylephrine. SVV and PPV decreased in
both groups to a comparable amount, but in the non-parasym-
pathically blocked patients bradycardia results in an overall
reduction in CO (2).
An undeniable increase in CO in concert with stable HR in
the parasympathically blocked patients confirms a recruitment
of blood volume from capacitance vessels.
However, in the non-parasympathically blocked patients,
there was an equivalent effect on SV, SVV, and PPV, but a
decreased CO, most probably because of the induced brady-
cardia. Although the decrease in SVV still reflects an optimi-
zation of the position on the Frank-Starling curve, this may be
partly attributable to increased venous pooling as a result of
decreased CO.
If a clinician were to rely only on a decreased SVV or
decreased variation of pulse oximetric plethysmographic wave-
form amplitude (POP), this may falsely suggest an increased
CO by virtue of increased SV, whereas the ultimate macrohe-
modynamic result is a decrease in CO and tissue perfusion. In
addition to these negative systemic effects, the combination of
pulmonary vasoconstriction and increased venous return by
phenylephrine may put additional stress on the right heart (4).
We suggest that administration of phenylephrine in para-
sympathically blocked patients provides an increased perfusion
pressure with positive effect on cardiac output. However, as
higher doses of phenylephrine are well known for their nega-
tive effects on cardiac output and tissue perfusion (3) and
because their effects are dependent on several complex inter-
actions, we recommend making use of advanced (noninvasive)
monitoring of CO and SVV during administration of this
vasopressor in clinical practice.
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